Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis evaluated tofacitinib persistence in patients with RA in long‐term extension (LTE) studies up to 9.5 years. METHODS: Data were pooled from two LTE studies: ORAL Sequel (NCT...

Descripción completa

Detalles Bibliográficos
Autores principales: Pope, Janet E., Keystone, Edward, Jamal, Shahin, Wang, Lisy, Fallon, Lara, Woolcott, John, Lazariciu, Irina, Chapman, Douglass, Haraoui, Boulos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857988/
https://www.ncbi.nlm.nih.gov/pubmed/31777783
http://dx.doi.org/10.1002/acr2.1010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857988/
https://www.ncbi.nlm.nih.gov/pubmed/31777783
http://dx.doi.org/10.1002/acr2.1010

Ejemplares similares